Clinicopathologic significance of the mutations of the Epidermal Growth Factor Receptor gene in patients with non-small cell lung cancerTOMIZAWA, Yoshio; IIJIMA, Hironobu; DOBASHI, Kunio et al.Clinical cancer research. 2005, Vol 11, Num 19, pp 6816-6822, issn 1078-0432, 7 p., 1Article

Genetic and epigenetic inactivation of LTF gene at 3p21.3 in lung cancersIIJIMA, Hironobu; TOMIZAWA, Yoshio; IWASAKI, Yasuki et al.International journal of cancer. 2006, Vol 118, Num 4, pp 797-801, issn 0020-7136, 5 p.Article

Clinicopathological significance of aberrant methylation of RARβ2 at 3p24, RASSF1A at 3p21.3, and FHIT at 3p14.2 in patients with non-small cell lung cancerTOMIZAWA, Yoshio; IIJIMA, Hironobu; NOMOTO, Taisuke et al.Lung cancer. 2004, Vol 46, Num 3, pp 305-312, issn 0169-5002, 8 p.Article

A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancerKAIRA, Kyoichi; SUNAGA, Noriaki; YOSHII, Akihiro et al.Lung cancer. 2010, Vol 69, Num 1, pp 99-104, issn 0169-5002, 6 p.Article

Phase 2 study of S-1 plus carboplatin in patients with advanced non-small cell lung cancerKAIRA, Kyoichi; SUNAGA, Noriaki; HISADA, Takeshi et al.Lung cancer. 2010, Vol 68, Num 2, pp 253-257, issn 0169-5002, 5 p.Article

Phase ii prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapySUNAGA, Noriaki; TOMIZAWA, Yoshio; SAITO, Ryusei et al.Lung cancer. 2007, Vol 56, Num 3, pp 383-389, issn 0169-5002, 7 p.Article